Revenue segments as reported by the company.

Grant revenue

Clinical trial revenue

Contract revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Research and development

Selling and marketing

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Longeveron

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longeveron reports promising Q1 results, secures funding for growth

Longeveron's Q1 2024 earnings call highlighted positive Phase I results for HLHS and cost management efforts. The company secured funding for further development and welcomed new board members. Challenges include regulatory hurdles and market competition, but opportunities lie in expanding therapeutic applications and revenue growth potential.

Longeveron reports positive Q2 results, eyes contract services expansion

Longeveron's Q2 2024 earnings call highlighted strong performance in trials and financials, with a focus on HLHS program advancement and contract services expansion. The company faces challenges in addressing analyst inquiries and maximizing its contract services business potential, but has opportunities for revenue growth and leveraging positive trial outcomes.

Longeveron reports robust revenue growth and progresses towards FDA approval

Longeveron's Q3 2024 performance reflects strong revenue growth and advancements in regulatory pathways for their product candidate, Lomecel-B, across multiple therapeutic areas.
The company's focus on cellular therapies aligns with a lucrative market potential in the U.S., but funding needs for accelerated activities and competitive challenges pose considerations for future strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Biofrontera

Blink Charging

Cortexyme Inc

Intercept Pharma

Lemonade

Prelude Therapeutics

Reliance Global Group

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on InvestorPlace.

The 10 Most Shorted Stocks Right Now for Friday, Dec. 17

Greenland Technologies Holding Corporation

iSpecimen

Petros Pharmaceuticals

Vallon Pharmaceuticals

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile examples of short-squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On Record

LGVN stock has soared in 2021 with the latest upbeat FDA news but a closer look at Longeveron's financials tells a different story. The post Why Longeveron's Good News Isn't Telling Us the Whole Truth appeared first on InvestorPlace.

Why Longeveron's Good News Isn't Telling Us the Whole Truth

No, but make sure you understand what you're getting into.

Is It Too Late to Buy Longeveron Stock?

Biogen

Prometheus Biosciences

Check out these biotech stocks turning heads in the stock market now.

3 Biotech Stocks To Watch On Pfizer's Latest Omicron Update

Halozyme Therapeutics

Prothena

Cassava Sciences Inc

Sesen Bio Inc.

Takeda Pharmaceutical

Teva Pharmaceutical

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

Centessa Pharmaceuticals PLC

Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy.

2 Big Stock Bets That Are Insiders Are Buying Now

MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

The biotech stock is now up 171.5% year to date.

Why Longeveron Stock Skyrockted 661.2% in November

Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.

Is Longeveron a Good Biotech Stock to Buy?

MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced private placement of common stock and warrants.

Longeveron Inc. Announces Closing of a $20.5 Million Private Placement

GlaxoSmithKline

Merck

Health care stocks seem to be in vogue again as the Omicron Covid variant spreads globally.

Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know

An orphan drug designation for the treatment of a rare heart condition is pushing the biotech stock higher.

Here's Why Longeveron Is Surging Today

The stock price of Longeveron Inc. (NASDAQ: LGVN) increased by over 35% during intraday trading today. This is why it happened.

Longeveron (LGVN): Why The Price Surged Today

The FDA has granted Orphan Drug designation to Longeveron Inc's (NASDAQ: LGVN) lead investigational product Lomecel-B for Hypoplastic left heart syndrome (HLHS). Lomecel-B is a cell-based therapy product derived from culture-expanded medicinal signaling cells (MSCs), sourced from the bone marrow of young, healthy adult donors.

Longeveron Shares Gain After Lead Product Gets FDA Orphan Drug Tag For Type Of Congenital Heart Defect

Longeveron Inc (NASDAQ: LGVN) has announced a private placement of approximately $20.5 million of its common stock and warrants. The purchase price for one share of common stock and one corresponding warrant will be $17.50.

Longeveron Shares Fall After Raising $20M Capital Via Equity

The stock price of Longeveron Inc (NASDAQ: LGVN) fell by over 15% pre-market today. This is why it happened.

Longeveron (LGVN) Stock: Why The Price Substantially Dropped Today

MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.

Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement

Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B. What Happened: Florida-based Longeverson said it has entered into a sponsored clinical research agreement with Japan's National Center for Geriatrics and Gerontology and the Juntendo University Hospital to study Lomcecel-B in older, frail Japanese subjects.

Longeveron Announces Clinical Collaboration To Study Cell Therapy Aging Treatment In Japan: Why It Matters

New trial is in collaboration with Japan's National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital New trial is in collaboration with Japan's National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital

Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

LGVN stock is speculative and Longeveron's fiscal performance has some sticking points. Still, an FDA approval could propel the stock higher.

Even After a Blistering Rally, Longeveron Is Still Buyable

Novavax

Teladoc

Could rising coronavirus cases globally see these health care stocks be put back into the limelight?

4 Hot Health Care Stocks To Watch Right Now

Short sellers really should have thought twice before betting huge against a company literally named Longeveron LGVN, +145.64%.

MemeMoney: Longeveron is the short squeeze Reddit Apes can give thanks for this year

Why Longeveron Stock Is Skyrocketing Today

Today, investors in Longeveron are once again seeing tremendous upside momentum as LGVN stock surges another 80%. The post LGVN Stock: 7 Things to Know as Longeveron Rockets 100% Higher appeared first on InvestorPlace.

News for Longeveron Stock (LGVN)